Marker Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Marker Therapeutics, Inc.'s free cash flow has decreased 10.12% from $-10.91M last year to $-12.01M, signaling decreasing performance

Marker Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Marker Therapeutics, Inc. has insufficient data to evaluate this check.

Marker Therapeutics, Inc. has a net cash position, so leverage is healthy.

Marker Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Marker Therapeutics, Inc.'s profit margin has decreased (219.59%) in the last year from -162.82% to -520.35%, signaling decreasing performance

Marker Therapeutics, Inc.'s short-term assets of $19.07M exceed its short-term liabilities of $2.27M

Marker Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Marker Therapeutics, Inc.'s return on equity of -73.29%, is lower than 15.00%, indicating bad performance

Marker Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Marker Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Marker Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Marker Therapeutics, Inc. has negative free cash flow, indicating cash burn

Marker Therapeutics, Inc.'s yearly earnings has decreased 13.35% since last year from $-10.73M to $-12.16M, signaling decreasing performance

Marker Therapeutics, Inc.'s yearly revenue has increased 53.81M% since last year from $6.59M to $3.55T, signaling increasing performance

ROIC -89.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Marker Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Marker Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Marker Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Marker Therapeutics, Inc. is undervalued relative to its fair value price of 1.41M based on Discounted Cash Flow model

Marker Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Marker Therapeutics, Inc. is undervalued relative to its fair value price of 1.49M based on EBITDA multiple model

Marker Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Marker Therapeutics, Inc. has insufficient data to evaluate this check.

Marker Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Marker Therapeutics, Inc. has a price-to-book ratio of 1.61x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Marker Therapeutics, Inc. has a price-to-sales ratio of 10.61x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue